Leadership
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
David Or Goliath: Where Is Innovation Winning Through?
With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.
Latest From Leadership
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
Corporate Affairs: Biopharma’s First Line Of Defense Against Scrutiny
Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.
GSK's Hal Barron On R&D Progress At Two-Year Mark
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
C-Suite Snippets: Targeting Metastasis In Cancer Therapy
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.
C-Suite Snippets: A Fresh View From Old Science
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.